Brutalist Biotech

• Ronovo Surgical raises $67M for modular laparoscopic robot with J&J backing (4h)
• OraSure comes under investor pressure, with potential proxy fight: report (6h)
• FDA misinterpreted efficacy data that prompted DMD rejection, Capricor claims (6h)
• Pfizer vet takes CEO post at new, phase 3-ready regenerative medicine biotech (8h)
• Eli Lilly invites biotechs to use its new AI platform to help develop their own drugs (10h)
• Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed in phase 2 (13h)
• LB Pharmaceuticals aims to raise $228M-plus in IPO to fund late-stage schizophrenia study (1d)
• Microbot Medical scores FDA clearance for remote-controlled cath lab system (1d)
• After FDA rejects Saol’s ultra-rare disease prospect, the biotech urges patients to press Congress (1d)
• Regeneron’s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies (1d)

• Lilly to give biotech startups access to AI tools (1h)
• Novartis to gain heart drug in $1.4B deal for Tourmaline Bio (6h)
• BioNTech says dual-acting lung cancer drug helped shrink tumors (22h)
• A new class of sleep drugs draws Wall Street’s attention (1d)
• Pfizer, BioNTech showcase new data supporting COVID booster (1d)
• New Summit data clouds approval pathway in lung cancer (1d)
• Rapport shares double on better-than-expected seizure drug data (1d)
• A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria (1d)
• Driving precision oncology development: Integrated biomarker testing solutions that deliver impact (1d)
• How sponsors are staying ahead in the obesity trial landscape (1d)

• Endpoints livestream: Will the XBI ever go up again? (3h)
• Lundbeck to transfer commercial drugs to three partners in 27 markets (3h)
• HHS outlines vaccine, drug strategy in new MAHA report (4h)
• Eric Green, who the Trump administration ousted from NIH, urges optimism (4h)
• Samsung Bio secures $1.3B contract with ‘large-sized’ US pharma customer (5h)
• Regeneron and Sandoz patent deal clears path for Eylea biosimilar in 2026 (5h)
• Trump may exempt some pharma products from tariffs in future trade deals (6h)
• Ideaya touts trio of cancer drugs as it eyes spot in precision oncology market (6h)
• Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot (7h)
• Eli Lilly offers AI models to biotechs with TuneLab launch (11h)

• Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform (43m)
• Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises (6h)
• FDA Turns Away Ultra-Rare Disease Therapy (8h)
• BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC (9h)
• Neuroscience Biotech LB Files for $228M IPO to Support Phase III Plans (9h)
• Novartis Deals in Cardio Again, Dropping $1.4B to Acquire Tourmaline (9h)
• Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’ (9h)
• As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof Point (17h)
• Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline (18h)
• If Data Is the New Oil, AI Is the Refinery (1d)

• RFK Jr. ally’s ‘smoking gun’ study on vaccines and chronic illness is fundamentally flawed (1h)
• Dozens of lawmakers urge HHS to abandon a pilot initiative for the controversial 340B program (1h)
• An API supplier in India wants you to know its metal detector is working just fine (1h)
• CMS delays rule requiring Medicare Advantage insurers to remind members of unused benefits (2h)
• Kennedy looks to add new members to federal vaccine panel (2h)
• Apple introduces smartwatch feature designed to detect high blood pressure (3h)
• MAHA Commission promotes fitness as a vital sign for children. What does that mean? (4h)
• Kennedy makes his formal pitch to fight chronic disease in new MAHA report (4h)
• Study links marijuana use during IVF to higher risk of abnormal embryos (7h)
• How Trump tax bills help health care giants avoid taxes (7h)

• Integra Therapeutics Raises €10.7 Million to Advance Gene Writing Platform and CAR-T Validation (5h)
• CHARM Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitors for AML (5h)
• Ketryx Gets $39 Million to Expand AI Compliance Infrastructure for Life Sciences (6h)
• Enveda Secures $150M Series D, Advances Lead Program & Adds Ex-Pfizer R&D Chief to Board (8h)
• Lilly Offers Biotechs Access to AI Models Trained on $1B in Proprietary Drug Discovery Data (8h)
• Proscia Launches New AI Pathology Platform to Link Patients With Drug Trials (9h)
• LatchBio Publishes 25-Million-Cell Open-Source Spatial Transcriptomics Atlas (11h)
• Digital Twins in Rare Diseases: From Virtual Trials to Personalized Care (1d)
• Potential Breakthrough in Cell Reprogramming as OpenAI and Retro Biosciences Report 50x Pluripotency Marker Expression Gains (2w)
• Immunai Opens Free Single-Cell Sequencing Program for Academic Labs (3w)

Drug Channels

• Drug Channels Leadership Forum 2026: Full Agenda Now Available (Spoiler: Even more awesome than 2025!) (17h)
• If Banks Sync Data in Real Time, Why Can't Patient Services? (4d)
• Hubs: The Bridge Between Patients and Providers (2w)
• Why the Pharmacy Supply Chain Is Broken and How SmithRx Is Fixing It (3w)
• Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes (3w)
• Solving the Gross-to-Net Bubble With Better Data (4w)
• Solving the Gross-to-Net Bubble with Better Data (4w)
• Pharmacy Shakeout: Why U.S. Drugstores Are Disappearing (4w)
• Patient Support’s Perfect Storm in 2025: Hits, Misses, and Surprises (1mo)
• Markup Madness 2025: Hospitals, Insurers, and the Broken Buy-and-Bill Market for Biosimilars (1mo)

• Servier acquires Kaerus Bioscience’s FXS candidate for US$450m (16h)
• NRG Therapeutics Ltd bags £50m in Series B financing (1d)
• BioFlo® 120 – Performance Meets Value (1d)
• BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla (2d)
• Alt protein: EASAC sees immediate need for action (2d)
• Microbiome play MRM Health NV raises €55m in Series B (5d)
• Novartis AG invests US$200m in lacklustre Parkinson’s target (6d)
• Cytokinetics’ Aficamten with breakthrough Phase III results (6d)
• Polpharma Biologics secures distribution of upcoming biosimilars (1w)
• Genentech inks US$400m IBD deal with OMass Therapeutics (1w)

Drug Hunter

• PF-07293893 (1h)
• Lessons in LAI: Discovery of a Long-Acting Injectable TAK1 Inhibitor (1d)
• Glossary: AI for Drug Discovery (1d)
• Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake (4d)
• PF-07853578 (5d)
• darovasertib (NYP-LXS196, IDE-196) (6d)
• Drug-Induced Phospholipidosis (6d)
• sevabertinib (BAY 2927088) (1w)
• zongertinib (BI 1810631) (1w)
• Opposing Views of the Immunology Target NEK7 (2w)

• Top biotech deals in August 2025 (9h)
• Advanced expression vector design to overcome challenges in developing multichain biotherapeutics (14h)
• With Lykos CRL now public, FDA opens new era of accountability (1d)
• Closing treatment gaps in yellow fever: are germ-free egg-based vaccines the answer? (4d)
• Navigating the biotech development journey from first steps to global scale with Lonza (4d)
• Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand (6d)
• How are biotechs tackling malaria? (6d)
• The biggest biotech funding rounds in August 2025 (1w)
• Blood Cancer Awareness Month: What biotech holds in store (1w)
• Can genetically modified crops help us adapt to climate change? (2w)

Bio IT World

• First-in-Class Dietary Supplement a Potentially Big Win for Babies (7h)
• Microbiome-Based Therapies Hold Promise for Chronic Diseases (5d)
• Psilocybin Being Investigated as an Anti-Aging Agent (6d)
• Machine Learning Penetrance Score Predicts Genetic Variant Impacts (1w)
• Ultima’s ppmSeq Pushes Sequencing to New Levels of Accuracy (2w)
• Follow the Money: Rheumatoid Arthritis Therapy, Novel Next-Gen Biosensor, More (2w)
• BioMed X, Novo Nordisk Collaboration, 10x Genomics Launches Platform Addition, More (2w)
• Bioprocessing Summit Honors LISURE as Best of Show Winner (3w)
• Family-Based Genomics Benchmark Promises More Accurate Variant Detection (3w)
• Nature’s Most Promising Bioactives to Speed Up Evidence-Based Drug Discovery (3w)

• Alzheimer’s Vaccine Candidate ALZ-101 Begins Phase II Clinical Study (9h)
• Servier Buys Fragile X Syndrome Candidate for up to $450M (23h)
• Prior Dengue Infection Rewires Immunity, Boosts Vaccine Response (23h)
• Flu Severity in Older Adults Mediated by ApoD Regulation of Innate Antiviral Immunity (1d)
• Cancer Cells Use Backup Routes to Fuel Their Growth (1d)
• People Power in AI’s Penetration in Bioprocessing (1d)
• Public Model for Predicting Long-Term Cell Stability (1d)
• Tech and Teamwork Key to Building CGT Capacity in Smaller Markets (1d)
• Clarification Contributes More to CQA Than Realized (1d)
• Precision Microfluidics for RNA and Gene Therapy Applications (1d)

• FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer (49m)
• Change of Season Musings As A Breast Cancer Survivor (2h)
• Lunsumio plus Polivy Associated With Responses in MCL (3h)
• Standing Up to Cancer with Lynch Syndrome (5h)
• Zidesamtinib Elicits Responses in ROS1-Positive NSCLC (6h)
• Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC (6h)
• Suleika Jaouad on Why Self-Advocacy Matters for Patients With Cancer (9h)
• The Seasons of Cancer (1d)
• What Patients With Lung Cancer Need to Know About KRAS G12C Mutations (1d)
• Ivonescimab Plus Chemo Delays NSCLC Progression (1d)

Contract Pharma*

• Packaging Innovation with Purpose (2h)
• Medable Launches Agent Studio (3h)
• Abselion Launches AAVX and AAV9 Quantification Kits (4h)
• Parexel Establishes New Global HQ in Raleigh, NC (4h)
• Circle Pharma Partners with Eli Lilly to Boost AI-Driven Drug Discovery (7h)
• Ethris & Evonik Join Forces to Advance Targeted mRNA Vaccines and Therapies (7h)
• Inizio Taps Ryan Quigley as CEO (8h)
• Scenic Biotech Appoints Roland W. Bürli Chief Scientific Officer (9h)
• Novartis to Acquire Tourmaline Bio for $1.4 Billion (9h)
• Maximizing Bioavailability and Commercial Success with Softgels (1d)

• Quotient Sciences and CPI launch RNA drug development venture (13h)
• Bluejay begins phase 3 trial of brelovitug for hepatitis D (13h)
• Eisai unveils promising phase 1b data for narcolepsy drug E2086 (1d)
• AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025 (5d)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (6d)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (6d)
• Polpharma Biologics and MS Pharma partner to expand biosimilar access (1w)
• eXmoor and Anthony Nolan partner to streamline cell therapy development (1w)
• FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease (1w)
• Lilly receives UK approval for pirtobrutinib in relapsed blood cancers (1w)

• Corewell Health Touts Success of Virtual Lifestyle Medicine Program with Nudj Health (26m)
• Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds (1h)
• The Most Powerful Tool in Healthcare Marketing: A Patient’s Voice (7h)
• From Hospital to Home Without the Headaches: How Technology Can Smooth the Transition (8h)
• Judge Advances Particle Health’s Antitrust Lawsuit Against Epic (20h)
• Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels (21h)
• WeightWatchers Introduces New Menopause Program (23h)
• Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt (1d)
• Why Hormone Health Should Be A Standard Part Of Men’s Healthcare (1d)
• SOAR Act Would Help Individuals Relying on Oxygen Thrive (1d)

• Nobel laureate David Baltimore dies at 87 (2h)
• Opinion: Exploitation persists in academic science—here’s what we can do (3h)
• Business briefing for September 9 (4h)
• Greening Chemistry: Don’t let resistance to change stop students from changing the world (4h)
• Manganese edges into the realm of noble-metal photochemistry (5h)
• Joseph S. Francisco named 2025 Pauling Medal Award winner (6h)
• Scientists uncover weakness in brain cancer’s armor (23h)
• Scientists in Congress: 50 years of ACS Public Policy Fellowships (1d)
• For director-at-large: Anna Cavinato (1d)
• For director-at-large: Malika Jeffries-EL (1d)

The Pharma Letter*

• Scenic Biotech names Roland Bürli as CSO (6h)
• Patients the ‘North Star’ for Sionna-bound Caroline Stark Beer (6h)
• Brinsupri massively overpriced at current rates, claims ICER (7h)
• Novartis to acquire Tourmaline Bio (8h)
• FDA rejection leaves Saol searching for a path forward in rare pediatric disease (8h)
• Rapport rockets on positive trial data for RAP219 (9h)
• Lilly rises on ‘striking and provocative’ Jaypirca results (9h)
• LB Pharma targets $250 million raise in bold IPO move (9h)
• Sandoz and Regeneron settle aflibercept dispute, paving way for US debut (10h)
• Arena BioWorks appoints Harvey Berger as CEO and shifts focus to biologics (10h)

• FDA Approves Intravesical Gemcitabine Delivery for Bladder Cancer (1h)
• Talquetamab Dose Modification Maintains Efficacy in Multiple Myeloma (3h)
• FDA Grants Breakthrough Therapy Designation to Olomorasib is KRAS G12C NSCLC (5h)
• I-DXd Shows Promise in Treating Extensive-Stage SCLC (7h)
• FDA Grants Orphan Drug Designation to Novel Glioblastoma Therapy (7h)
• Dr Mikhael on the State of Myeloma Research Funding in 2025 (9h)
• Future Directions and Conclusion (10h)
• Deciding When and How to Add Therapy for Steroid-Refractory GVHD (1d)
• Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence (1d)
• Frontline Osimertinib/Chemo Betters OS in EGFR+ Advanced NSCLC (1d)

• Degunkification (26m)
• Silent RNA (23h)
• An Underappreciated Fate of Drugs in Vivo (4d)
• Stirring Bars are Superstition? (5d)
• Nuclear Fusion in Palladium Metal. No, Really. (6d)
• A Condensate Dissolver (1w)
• RFK Jr. Must Go. And He's Not the Only One. (2w)
• Go Make Me Fifty Kilos of This Stuff (2w)
• Lithium Orotate Revisited (2w)
• When Do You Need a Macrocycle, Anyway? (3w)

• Lilly lines up Julianne Moore to front brain health campaign (3h)
• Lundbeck retreats from dozens of markets, slashing staff (4h)
• Lilly offers AI discovery models to biotech partners (6h)
• ICER says GLP-1s 'still have serious affordability issues' (7h)
• Lilly eyes earlier use of blood cancer drug Jaypirca (9h)
• NHS trust league tables arrive in UK health shakeup (10h)
• US anti-vaccine rhetoric trumpeted in UK, thanks to Reform (11h)
• After a long biotech IPO lull, LB Pharma chances its arm (12h)
• Novartis nabs cardio drug with $1.4bn Tourmaline buy (13h)
• Mixed data from lung cancer trials on show at WCLC (1d)

• New NICE thresholds is good news for ultra-rare disease drugs, says biotech (6h)
• Registration open for DDW Symposium in London (8h)
• Transforming drug discovery with AI and digital labs: Last chance to register (14h)
• Treatment for post-natal depression authorised in UK (1d)
• From knowledge to creation: keeping up with AI (1d)
• UK immigration system is a barrier to cancer research, says CRUK (1d)
• Webinar: Challenges and solutions in CGT drug discovery (1d)
• This week in drug discovery 1-5 September (4d)
• Research programme represents a “new frontier in vaccine science” (4d)
• Advancing gene-agnostic therapies for inherited retinal diseases (4d)